Philip Clarke
Philip Clarke
Professor of health economics, university of melbourne
Verified email at
Cited by
Cited by
A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68)
PM Clarke, AM Gray, A Briggs, AJ Farmer, P Fenn, RJ Stevens, ...
Diabetologia 47 (10), 1747-1759, 2004
Applied methods of cost-effectiveness analysis in healthcare
AM Gray, PM Clarke, JL Wolstenholme, S Wordsworth
Oxford University Press, 2011
Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62)
P Clarke, A Gray, R Holman
Medical Decision Making 22 (4), 340-349, 2002
Missing.... presumed at random: cost‐analysis of incomplete data
A Briggs, T Clark, J Wolstenholme, P Clarke
Health economics 12 (5), 377-392, 2003
The impact of diabetes‐related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65)
P Clarke, A Gray, R Legood, A Briggs, R Holman
Diabetic Medicine 20 (6), 442-450, 2003
UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom …
AJ Hayes, J Leal, AM Gray, RR Holman, PM Clarke
Diabetologia 56 (9), 1925-1933, 2013
Estimating the association between SF-12 responses and EQ-5D utility values by response mapping
AM Gray, O Rivero-Arias, PM Clarke
Medical Decision Making 26 (1), 18-29, 2006
Cost effectiveness of self monitoring of blood glucose in patients with non-insulin treated type 2 diabetes: economic evaluation of data from the DiGEM trial
J Simon, A Gray, P Clarke, A Wade, A Neil, A Farmer
bmj 336 (7654), 1177-1180, 2008
Applied methods of cost-benefit analysis in health care
E Frew
Oxford University Press, 2010
On the measurement of relative and absolute income-related health inequality
PM Clarke, UG Gerdtham, M Johannesson, K Bingefors, L Smith
Social science & medicine 55 (11), 1923-1928, 2002
Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72)
PM Clarke, AM Gray, A Briggs, RJ Stevens, DR Matthews, RR Holman
Diabetologia 48 (5), 868-877, 2005
Optimal recall length in survey design
PM Clarke, DG Fiebig, UG Gerdtham
Journal of health economics 27 (5), 1275-1284, 2008
Development of life-expectancy tables for people with type 2 diabetes
J Leal, AM Gray, PM Clarke
European heart journal 30 (7), 834-839, 2009
Horizontal inequities in Australia's mixed public/private health care system
E Van Doorslaer, P Clarke, E Savage, J Hall
Health Policy 86 (1), 97-108, 2008
Event rates, hospital utilization, and costs associated with major complications of diabetes: a multicountry comparative analysis
PM Clarke, P Glasziou, A Patel, J Chalmers, M Woodward, SB Harrap, ...
PLoS medicine 7 (2), e1000236, 2010
Survival of the fittest: retrospective cohort study of the longevity of Olympic medallists in the modern era
PM Clarke, SJ Walter, A Hayen, WJ Mallon, J Heijmans, DM Studdert
Bmj 345, 2012
Forgetting to remember or remembering to forget: a study of the recall period length in health care survey questions
G Kjellsson, P Clarke, UG Gerdtham
Journal of health economics 35, 34-46, 2014
Funding grant proposals for scientific research: retrospective analysis of scores by members of grant review panel
N Graves, AG Barnett, P Clarke
Bmj 343, 2011
Expenditures and prices of antihyperglycemic medications in the United States: 2002-2013
X Hua, N Carvalho, M Tew, ES Huang, WH Herman, P Clarke
Jama 315 (13), 1400-1402, 2016
Which health-related quality of life score? A comparison of alternative utility measures in patients with Type 2 diabetes in the ADVANCE trial
P Glasziou, J Alexander, E Beller, P Clarke
Health and quality of life outcomes 5 (1), 1-11, 2007
The system can't perform the operation now. Try again later.
Articles 1–20